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Background: Carboplatin and topotecan are commonly used in the
treatment of small cell lung cancer (SCLC); however, there are no
data for this combination in the first-line setting using weekly
topotecan. In this multicenter, community-based phase II trial, we
evaluated carboplatin and weekly topotecan in the previously un-
treated patients with extensive stage SCLC.
Methods: This trial was designed to achieve an objective response
rate (ORR) of 70% (  0.05;   0.20); secondary aims were to
assess time to progression, toxicity, and overall survival (OS).
Patients with Eastern Cooperative Oncology Group performance
status 0 to 1, measurable disease, and adequate organ function were
eligible. Treatment: carboplatin area under the concentration–time
curve  5 (intravenous) on day 1 and topotecan 4 mg/m2 (intrave-
nous) on days 1 and 8, every 21 days for up to six cycles, with
restaging every 6 weeks (per RECIST).
Results: Between June 2006 and November 2008, 61 patients were
enrolled. The median follow-up is 40 weeks (range 27–109 weeks).
Patient characteristics were as follows: median age 67 years (range
40–84 years); male, 53%; and Eastern Cooperative Oncology
Group performance status 0, 28%. Complete responses were seen in
two patients and partial responses in 33 patients; ORR was 57%
(95% confidence interval CI 44–70). Stable disease was seen in 12
patients (20%), and progressive disease was seen in two patients
(3%). The median time to progression was 5.5 months (95% CI
4.0–6.3 months). The median OS was 8.5 months (95% CI 7.2–11.4
months). One-year OS was 29%. Grade 3/4 toxicity in 5%:
neutropenia (66%), thrombocytopenia (48%), leukopenia (40%),
anemia (30%), fatigue (13%), dehydration (8%), infection (8%), and
pain (7%).
Conclusions: The ORR achieved with carboplatin and weekly
topotecan was less than the anticipated rate of 70%; however, it was
comparable with historical rates seen with other platinum doublets
in the first-line extensive stage SCLC setting. This regimen was
generally well tolerated, with myelosuppression as its primary tox-
icity.
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Platinum-based doublet chemotherapy is the standard first-line treatment for the patients with extensive stage small
cell lung cancer (ES-SCLC). Etoposide/platinum and irino-
tecan/platinum regimens have been extensively studied and
compared, resulting in response rates of 45 to 50%, median
time to progression (TTP) of 4 to 5 months, and median
survivals of 9 to 10 months.1–4
Topotecan is a DNA topoisomerase-I inhibitor ap-
proved for the treatment of sensitive-relapsed SCLC. This
approval was based on a randomized trial comparing a
consecutive 5-day every 3-week schedule of intravenous
topotecan with a triplet regimen of cyclophosphamide, doxo-
rubicin, and vincristine in the patients with sensitive-relapsed
SCLC.5 Topotecan was found to improve the quality of life
and symptom control over cyclophosphamide, doxorubicin,
and vincristine, despite having an equivalent response rate
(24%) and survival (25 weeks), and notable grade 4 hemato-
logic toxicity (neutropenia, 38%; anemia, 10%; and throm-
bocytopenia, 18%).
Topotecan/platinum doublets have been studied in
SCLC in phase II trials using a 5-day intravenous schedul-
ing.6–8 In addition, a randomized phase III trial of oral
topotecan/platinum versus etoposide/platinum was completed.9
In general, these regimens were well tolerated and result in
similar efficacy.
Weekly dosing of intravenous topotecan has been stud-
ied as an alternate schedule, which could minimize hemato-
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logic toxicity while preserving treatment benefit and improv-
ing patient convenience.10,11 Weekly scheduling has been
studied extensively in ovarian cancer and has been generally
well tolerated at a dose of 4 mg/m2.12–16 Our group has
studied weekly scheduling in the patients with relapsed SCLC
and as first-line SCLC therapy in poor performance status
(PS) patients.17,18 Weekly dosing was well tolerated and
associated with relatively low severe hematologic toxicity.
Our center conducted a phase I study (unpublished)
examining weekly topotecan and carboplatin in patients with
refractory/advanced solid tumors. Among 19 patients, grade 3
hematologic toxicity was limited to anemia and leukopenia;
no grade 4 hematologic and limited nonhematologic toxicity
were seen with topotecan. Herein, we report on a multicenter
phase II trial of carboplatin (area under the concentration–
time curve of 5 every 21) and weekly topotecan (4 mg/m2
administered on days 1 and 8) as a first-line therapy for the
previously untreated patients with ES-SCLC.
PATIENTS AND METHODS
This trial was initiated in June 2006 and completed
enrollment in November 2008. Participating centers included
the Sarah Cannon Research Institute and select sites from the
Sarah Cannon Oncology Research Consortium, a national
community-based research network.
Patients
Patients with histologically confirmed SCLC were en-
rolled. Patients with ES disease were eligible. This included
patients with stage IIIB and IV disease by the tumor node
metastasis system. Patients with large cell neuroendocrine
tumors or mixed small cell and non-small cell histolog-
ies were ineligible. Patients had measurable disease per
RECIST.19 Other eligibility criteria included the following:
age 18 years; no prior chemotherapy, primary radiation, or
biologic treatment; absence of active brain metastases; East-
ern Cooperative Oncology Group PS 0 to 1; and adequate
organ function (defined as absolute neutrophil count (ANC)
1.5  109/liter, platelet count 100  109/liter, serum
bilirubin 1.5  the upper limit of normal, serum aspartate
aminotransferase and alanine transaminase 3  upper limit
of normal, and serum creatinine 1.6 mg/dl).
Exclusion criteria included pregnancy or lactation, clin-
ically significant cardiovascular disease, and prior malig-
nancy within 3 years except nonmelanoma skin cancer and
cervical carcinoma in situ. All patients provided written
informed consent before enrollment.
Pretreatment Evaluation
Before treatment, patients were evaluated by history,
physical examination, and laboratory testing. Baseline tumor
staging was performed using computerized tomography (CT)
scans of the chest and abdomen, CT or magnetic resonance
imaging of the brain, and bone scan or positron emission
tomography.
Treatment Plan
All patients received carboplatin at a dose calculated to
produce an area under the concentration–time curve of 5.0
mg/ml/min, administered intravenously on day 1, and topo-
tecan 4 mg/m2 intravenously on days 1 and 8 every 21 days
for a maximum of six cycles (Figure 1). The carboplatin dose
was calculated using the method described by Calvert et al.20
Patients were restaged with CT scans every two cycles (per
RECIST).
Dose modifications were based on ANC and platelet
counts on days 1 and 8 of each cycle; and doses were not
increased once modified. No adjustments were required if the
ANC was 1.5  109/lier and platelet count 100 
109/liter. If the ANC was 1.0 to 1.49  109/liter or platelets
75 to 99  109/liter, chemotherapy was reduced 25%. If the
ANC was 1.0  109/liter or platelets 75  109/liter on
day 1, chemotherapy was held until counts recovered to
baseline parameters when chemotherapy could be resumed
with a 25% dose reduction. If the ANC was 1.0  109/liter
or platelets 75  109/liter on day 8, topotecan was omitted,
and both drugs were reduced 25% with subsequent cycles. If
the counts did not recover within 3 weeks, the patient came
off study. Patients requiring hospitalization for neutropenia
and fever had 25% dose reductions. Chemotherapy was also
reduced 25% for grade 3/4 nonhematologic toxicity.
Toxicity assessments were made according to the com-
mon terminology criteria for adverse events (version 3.0) of
the National Cancer Institute. Cytokines were not adminis-
tered during the first course of treatment; however, prophy-
lactic granulocyte colony-stimulating factor for patients ex-
periencing febrile neutropenia was permitted at the discretion
of the treating physician and was not to substitute for man-
dated dose reductions. Routine antiemetics were used as
premedication.
This trial was approved by the institutional review
boards of all participating institutions. Topotecan was sup-
plied by GlaxoSmithKline (Philadelphia, PA). A commer-
cially available form of carboplatin was used.
Definition of Response
All patients were evaluated for response by RECIST
criteria. The final response category assigned represented the
best response obtained during treatment.
Statistical Methods
The primary objective of this phase II study was to
assess the objective response rate. Secondary objectives were
FIGURE 1. Trial schema.
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to assess toxicity, TTP, duration of response, and overall
survival (OS). This trial used a MiniMax 2-stage statistical
design. For a total of 60 subjects, 28 would be accrued during
stage 1 and 32 during stage 2. If 15 or fewer responses were
observed during the first stage, then the trial would be
stopped early or amended. With an anticipated overall re-
sponse rate of 70%, there was a 5% probability that the trial
would be stopped in stage 1. The alpha level of this design
was 0.05, and the power was 0.8. TTP was defined as the
interval between the start date of treatment and the date of
occurrence of progressive disease (PD). If intolerable toxicity
or discontinuation of treatment secondary to toxicity oc-
curred, the patient was considered assessable, but it was
classified as a treatment failure. If other antitumor therapy
was initiated before PD occurred, the patient was censored on
the date on which the other therapy began. If a patient was
lost to follow-up, the patient was censored on the date of last
contact. OS was measured from the date of study entry until
the date of death. Survival curves were estimated using the
method of Kaplan and Meier.21
Toxicity was assessed after the first 10 patients were
treated. Expected toxicities during this treatment included
myelosuppression and thrombocytopenia. If grade 4 cytope-
nias were seen in more than 4 of the first 10 patients, further
accrual would be stopped and a dose reduction in chemother-
apy considered.
RESULTS
Patient Characteristics
Sixty-one patients were enrolled from June 2006 to
November 2008, 54% from outside of our Nashville site.
Baseline characteristics for all patients are described in Table
1. The median age was 67 years (range 40–84 years).
Thirty-two (53%) patients were men, and 29 patients were
women. Eastern Cooperative Oncology Group PS was 0 in 17
(28%) patients and 1 in 43 (71%) patients.
Treatment Received
The median follow-up is 40 weeks (range 27–109
weeks). Sixty-three percent of planned treatment was admin-
istered. Twenty-three (38%) patients completed six cycles of
chemotherapy (median 4 cycles, range 1–6 cycles). Seventy-
five percent of patients had at least one dose reduction; and
most of these (91%) were because of hematologic toxicity.
Seventy-three percent of patients received at least one dose of
granulocyte colony-stimulating factor. Twenty-five (41%) pa-
tients received red blood cell transfusions (median 2); and 13
(21%) patients received platelet transfusions. Twelve (20%)
patients were not evaluable for response because of patient death
(five patients), intercurrent illness (one patient), patient request
(one patient), poor subjective response (three patients), or treat-
ment related toxicity (two patients). All these patients were
included in the efficacy analyses.
Response
Sixty-one patients are included in the response analysis
(Table 2). Complete responses were seen in 2 (3%) patients
and partial responses in 33 (54%) patients, for an overall
response rate of 57% (95% confidence interval CI 44–70).
Twelve (20%) patients had stable disease, and two (3%)
patients had PD. The median response duration was 4.4
months (95% CI 3.2–6.9 months).
Time to Progression and Survival
The median TTP was 5.5 months (95% CI 4.0–6.3
months) (Figure 2). The median OS was 8.5 months (95% CI
7.2–11.4 months) (Figure 3). One-year OS was 29%. At the
time of this analysis, 15 (25%) patients were alive.
FIGURE 2. Time to progression.
TABLE 2. Response Rates (n  61)
Response n (%)
Complete 2 (3)
Partial 33 (54)
Stable disease 12 (20)
Progression 2 (3)
Not evaluablea 12 (20)
a Not evaluable due to patient death (five patients), intercurrent illness (one patient),
patient request (one patient), poor subjective response (three patients), and treatment-
related toxicities (two patients).
TABLE 1. Baseline Characteristics
Characteristic Patients, n (%)
Age (yr)
Median 67
Range 40–84
Gender
Male 32 (53)
Female 29 (47)
ECOG PS
0 17 (28)
1 43 (71)a
Location of treatment facility
Nashville site 28 (46)
Consortium sites 33 (54)
a One patient had a PS of 2.
ECOG, Eastern Cooperative Oncology Group; PS, performance status.
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Treatment-Related Toxicity
Treatment-related toxicity is summarized in Table 3. In
general, treatment was well tolerated although severe (grade
3/4) myelosuppresion was common, and it included neutro-
penia (66%), leukopenia (40%), anemia (30%), and throm-
bocytopenia (48%). Neutropenic fever occurred in three pa-
tients overall. Nine (15%) patients were hospitalized for
myelosuppression. The most common (5%) grade 3/4 non-
hematologic toxicities included dehydration (8%), fatigue
(13%), infection (8%), and pain (7%). All other grade 3/4
toxicities were uncommon (5%). There was one potential
treatment-related death because of sepsis related to a perfo-
rated diverticulum.
DISCUSSION
This phase II trial was designed to examine carboplatin
and weekly topotecan in the previously untreated patients
with ES-SCLC. The 57% response rate was lower than the
estimated rate of 70% but similar to other first-line platinum
doublet regimens in a first-line ES-SCLC setting. Likewise,
the disease control rate of 77%, median TTP, and OS are
comparable with outcomes with first-line etoposide/platinum
and irinotecan/platinum regimens.
Weekly scheduling of topotecan has been studied as a
means of reducing myelosuppression, preserving treatment
efficacy, and improving patient convenience over consecutive
5-day intravenous dosing. This schedule has been extensively
studied in ovarian cancer (at a dose of 4 mg/m2), where it has
been shown to be well tolerated and active as a single agent
in the relapsed setting. Weekly topotecan (2–2.5 mg/m2) has
also been studied in combination with carboplatin in small
phase I/II settings in patients with advanced ovarian and
peritoneal cancer.22–24 This regimen has been found to be
generally well tolerated and associated with responses in the
patients previously treated with platinum-based therapy.
Data on weekly scheduling of topotecan in SCLC has
been limited to small phase II studies at our center17,18 and by
Shah et al.25 In each of these trials, weekly topotecan (4
mg/m2) could be safely administered, but response efficacy
was low. Indeed, this led to a subsequent phase II trial at our
center looking at a higher dose of weekly topotecan (6 mg/m2
weekly for 6 of 8 weeks).26 Unfortunately, a higher dose
could not be consistently delivered because of hematologic
toxicity.
In our doublet trial, there were high rates of myelosup-
pression, necessitating dose modifications and leading to
hospitalizations in 15% of patients. Importantly, the rates of
neutropenia seem lower than what is often observed with
etoposide/platinum regimens where rates can exceed 80%.1,3
The rates of anemia and thrombocytopenia were higher than
expected with etoposide or irinotecan, presumably because of
the addition of carboplatin.
In conclusion, the objective response rate achieved with
carboplatin and weekly topotecan was less than the antici-
pated rate of 70%; however, it was comparable with historical
rates seen with other platinum doublets in the first-line
ES-SCLC setting. This regimen was generally safe, with
myelosuppression as its primary toxicity. This schedule of-
fers a more convenient administration than consecutive 5-day
intravenous dosing, while being well tolerated.
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